Mr. Alvaro Torres reports

KHIRON LIFE SCIENCES ENTERS INTO $25 MILLION BOUGHT DEAL EQUITY FINANCING

Khiron Life Sciences Corp. has entered into an agreement with Canaccord Genuity Corp. and BMO Capital Markets as co-lead underwriters and joint bookrunners, on behalf of a syndicate of underwriters, pursuant to which the underwriters have agreed to purchase 8,621,000 common shares of the company on a bought deal basis pursuant to a short form prospectus offering, subject to all required regulatory approvals, at a price per common share of $2.90, for gross proceeds of $25,000,900.

The company has also granted the underwriters an overallotment option to purchase up to an additional 15 per cent of the common shares at the issue price at any time on or prior to the date that is 30 days following the closing of the offering. If this option is exercised in full, the company will receive an additional $3,750,135 in gross proceeds for total aggregate gross proceeds of $28,751,035.

The company intends to use the net proceeds of the offering to expand the company's operating capacity and for working capital requirements and other general corporate purposes.

In connection with the offering the company has agreed to pay the underwriters a cash commission equal to 6.0 per cent of the gross proceeds raised from the offering (including on any exercise of the overallotment option) and non-transferable compensation options equal to 6.0 per cent of the common shares sold under the offering. Each compensation option will be exercisable at the issue price to acquire one common share for a period of 24 months following the closing of the offering.

The closing date of the offering is scheduled to be on or about May 28, 2019, and is subject to certain conditions, including, but not limited to, the receipt of all necessary approvals, including the approval of the TSX Venture Exchange and the applicable securities regulatory authorities.

About Khiron Life Sciences Corp.

Khiron is positioned to be the dominant integrated cannabis company in Latin America. Khiron has core operations in Latin America and is fully licensed in the country for the cultivation, production, domestic distribution and international export of both THC (tetrahydrocannabinol) and CBD (cannabidiol) medical cannabis. In May, 2018, Khiron listed on the TSX Venture Exchange, becoming the first Colombian-based medical cannabis company to trade on any exchange globally.

We seek Safe Harbor.